The AmpliChip CYP450 genotyping test: Integrating a new clinical tool (Q34537662)

2 August 2017

1 reference

title

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool (English)

1 reference

2 August 2017

1 reference

Jose de Leon

1

1 reference

2 August 2017

Margaret T Susce

series ordinal

2

1 reference

2 August 2017

Elaina Murray-Carmichael

series ordinal

3

1 reference

2 August 2017

1 January 2006

1 reference

Molecular Diagnosis and Therapy

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

3

1 reference

2 August 2017

135-151

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256453

2 August 2017

0 references

cites work

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacoeconomics of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Adverse drug reactions: definitions, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

21 January 2018

Adverse drug reactions

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Timing of new black box warnings and withdrawals for prescription medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

A vision for the future of genomics research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The anatomy of the human genome: a neo-Vesalian basis for medicine in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The challenge of integrating genetic medicine into primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenetics and pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Implications of the Human Genome Project for medical science.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenetics and pharmacogenomics: are they still promising?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Inherited variations in drug-metabolizing enzymes: significance in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Risperidone half-life in a patient taking paroxetine -- a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The CYP2C19 enzyme polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Development of analytical technology in pharmacogenetic research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenetics: the therapeutic drug monitoring of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Cost-effectiveness of therapeutic drug monitoring: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

How to read a paper. Papers that report diagnostic or screening tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Science, medicine, and the future: Pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Pharmacogenomics: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

An evidence-based guide to writing grant proposals for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The dosing of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

The economics of gene therapy and of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Why clinicians are natural bayesians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Systematic review: the relationship between clinical experience and quality of health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Clinical utility of thiopurine S-methyltransferase genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Drug-Related Morbidity and Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256453

Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study

21 January 2018

1 reference

12 December 2020

The DNA revolution. The secret of life.

1 reference

12 December 2020

Managing rapid metabolizers of antidepressants

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

1 reference

12 December 2020

Risperidone and cytochrome P450 3A

1 reference

12 December 2020

Variables associated with high olanzapine dosing in a state hospital.

1 reference

12 December 2020

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

1 reference

12 December 2020

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

12 December 2020

Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

1 reference

12 December 2020

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia

1 reference

12 December 2020

Incidence of serious adverse drug reactions in general practice: a prospective study

1 reference

12 December 2020

Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.

1 reference

12 December 2020

Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study

1 reference

12 December 2020

Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

1 reference

12 December 2020

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

1 reference

12 December 2020

A perspective on progress in pharmacogenomics

1 reference

12 December 2020

Pharmacogenomics: the implementation phase

1 reference

12 December 2020

Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds

1 reference

12 December 2020

Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.

1 reference

12 December 2020

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

12 December 2020

1 reference

12 December 2020

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

12 December 2020

Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4

1 reference

12 December 2020

Analysis of the direct cost of adverse drug reactions in hospitalised patients

1 reference

12 December 2020

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

12 December 2020

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?

1 reference

12 December 2020

An updated guide to genotype interpretation.

1 reference

12 December 2020

Pharmacogenomic testing: the cost factor.

1 reference

12 December 2020

Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders

1 reference

12 December 2020

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

12 December 2020

Genes arrayed out for you: the amazing world of microarrays.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256453

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference